July 16, 2024
4 min watch
Save
VIDEO: TakeAim study produces ‘exciting’ results in mutated acute myeloid leukemia
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Eric Winer, MD, discusses the results of the TakeAim study into acute myeloid leukemia, which he helped present at ASCO Annual Meeting.
Winer, a medical oncologist at Dana-Farber Cancer Institute, highlighted the study, which examined the use of emavusertib (Curis) in patients with acute myeloid leukemia who have experienced two different types of mutations.
“I think this is a very exciting molecule, and I think that when we combine emavusertib with other agents, we're going to see some really nice results and strong efficacy, and that's what's going to be moving forward in larger phase two trials right now,” Winer said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Winer reports serving on an advisory board for Curis and Takeda.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.